Serum elevation of CEA and CA 19-9 in an aggressive variant of prostatic carcinoma.
Brandes
A
A
Department of Radiation Oncology, University of Tuebingen, Germany. Angelika.Brandes@med.uni-tuebingen.de
Weinmann
M
M
Reichmann
U
U
Becker
G
G
Gärtner
H V
HV
Bamberg
M
M
D000230:Adenocarcinoma / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D018395:CA-19-9 Antigen / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology* / Q000628:therapy
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen